Cargando…

Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan

In clinical trials of tofacitinib for rheumatoid arthritis (RA), Japanese and Korean patients had higher incidence of herpes zoster (HZ) than subjects from elsewhere; however, post-market data from Asia are lacking. Hence, we investigated the incidence of HZ and its risk factors in Taiwanese RA pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yen-Ju, Chen, Yi-Ming, Huang, Wen-Nan, Chen, Hsin-Hua, Liao, Tsai-Ling, Chen, Jun-Peng, Hsieh, Tsu-Yi, Chen, Yi-Hsing, Chen, Der-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544164/
https://www.ncbi.nlm.nih.gov/pubmed/33031288
http://dx.doi.org/10.1097/MD.0000000000022504
_version_ 1783591802984464384
author Chen, Yen-Ju
Chen, Yi-Ming
Huang, Wen-Nan
Chen, Hsin-Hua
Liao, Tsai-Ling
Chen, Jun-Peng
Hsieh, Tsu-Yi
Chen, Yi-Hsing
Chen, Der-Yuan
author_facet Chen, Yen-Ju
Chen, Yi-Ming
Huang, Wen-Nan
Chen, Hsin-Hua
Liao, Tsai-Ling
Chen, Jun-Peng
Hsieh, Tsu-Yi
Chen, Yi-Hsing
Chen, Der-Yuan
author_sort Chen, Yen-Ju
collection PubMed
description In clinical trials of tofacitinib for rheumatoid arthritis (RA), Japanese and Korean patients had higher incidence of herpes zoster (HZ) than subjects from elsewhere; however, post-market data from Asia are lacking. Hence, we investigated the incidence of HZ and its risk factors in Taiwanese RA patients receiving tofacitinib. At a medical center in Taichung, Taiwan, we enrolled patients with active RA treated with tofacitinib between January 4, 2015 and December 9, 2017, following unsuccessful methotrexate therapy and no tofacitinib exposure RA patients as a control group. Demographic characteristics, interferon-gamma levels, and lymphocyte counts were compared. Among 125 tofacitinib-treated RA patients, 7 developed HZ, an incidence rate of 3.6/100 person-years. Patients with HZ had shorter disease duration than those without, but higher frequency of prior HZ. Baseline interferon-gamma levels and HLA-DR(+) activated T cell counts were positively correlated and significantly lower in patients with HZ than without. Strikingly, 5/7 HZ cases occurred within 4 months of starting tofacitinib therapy. Incidence of HZ in tofacitinib-treated Taiwanese RA patients is lower than rates in Japan or Korea, and commensurate with the global average. HZ may occur soon after commencing tofacitinib therapy. The role of interferon-gamma and activated T cells in tofacitinib-related HZ deserves further investigation.
format Online
Article
Text
id pubmed-7544164
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75441642020-10-30 Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan Chen, Yen-Ju Chen, Yi-Ming Huang, Wen-Nan Chen, Hsin-Hua Liao, Tsai-Ling Chen, Jun-Peng Hsieh, Tsu-Yi Chen, Yi-Hsing Chen, Der-Yuan Medicine (Baltimore) 6900 In clinical trials of tofacitinib for rheumatoid arthritis (RA), Japanese and Korean patients had higher incidence of herpes zoster (HZ) than subjects from elsewhere; however, post-market data from Asia are lacking. Hence, we investigated the incidence of HZ and its risk factors in Taiwanese RA patients receiving tofacitinib. At a medical center in Taichung, Taiwan, we enrolled patients with active RA treated with tofacitinib between January 4, 2015 and December 9, 2017, following unsuccessful methotrexate therapy and no tofacitinib exposure RA patients as a control group. Demographic characteristics, interferon-gamma levels, and lymphocyte counts were compared. Among 125 tofacitinib-treated RA patients, 7 developed HZ, an incidence rate of 3.6/100 person-years. Patients with HZ had shorter disease duration than those without, but higher frequency of prior HZ. Baseline interferon-gamma levels and HLA-DR(+) activated T cell counts were positively correlated and significantly lower in patients with HZ than without. Strikingly, 5/7 HZ cases occurred within 4 months of starting tofacitinib therapy. Incidence of HZ in tofacitinib-treated Taiwanese RA patients is lower than rates in Japan or Korea, and commensurate with the global average. HZ may occur soon after commencing tofacitinib therapy. The role of interferon-gamma and activated T cells in tofacitinib-related HZ deserves further investigation. Lippincott Williams & Wilkins 2020-10-09 /pmc/articles/PMC7544164/ /pubmed/33031288 http://dx.doi.org/10.1097/MD.0000000000022504 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 6900
Chen, Yen-Ju
Chen, Yi-Ming
Huang, Wen-Nan
Chen, Hsin-Hua
Liao, Tsai-Ling
Chen, Jun-Peng
Hsieh, Tsu-Yi
Chen, Yi-Hsing
Chen, Der-Yuan
Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan
title Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan
title_full Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan
title_fullStr Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan
title_full_unstemmed Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan
title_short Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan
title_sort herpes zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from taiwan
topic 6900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544164/
https://www.ncbi.nlm.nih.gov/pubmed/33031288
http://dx.doi.org/10.1097/MD.0000000000022504
work_keys_str_mv AT chenyenju herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan
AT chenyiming herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan
AT huangwennan herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan
AT chenhsinhua herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan
AT liaotsailing herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan
AT chenjunpeng herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan
AT hsiehtsuyi herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan
AT chenyihsing herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan
AT chenderyuan herpeszosterinrheumatoidarthritispatientsreceivingtofacitinibasinglecenterexperiencefromtaiwan